Anti-human CD64 Antibody (Clone: H22) | PA007393.h1Fs
$150.00 – $900.00
The human CD64 Fc blocking antibody (H22 Fc blocking antibody) is an anti-human Fc receptor antibody for human FcR blocking reagent. Various isotypes are available for certain applications. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
- Details & Specifications
- References
| Catalog No. | PA007393.h1Fs |
|---|---|
| Product Name | In vivo Grade Recombinant Anti-human CD64 Monoclonal Antibody, Human IgG1 Fc Silent Kappa (Clone: H22) |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | cluster of differentiation 64, Fc gamma RIA and Fc gamma RIB, Human Fc Receptor Blocking Antibody |
| Clone | H22. |
| Isotype | Human IgG1 kappa. |
| Source/Host | The anti-human CD64 monoclonal antibody (clone: H22) was produced in mammalian cells. |
| Specificity/Sensitivity | The in vivo grade recombinant mouse monoclonal antibody (clone: H22) specifically binds to human CD64. |
| Applications | ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD64 protein. Human Fc receptor blocking solution, human Fc receptor blocking reagent, and human Fc receptor blocking antibody. |
| Form Of Antibody | 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |
| Endotoxin | < 1 EU per 1 mg of the protein by the LAL method. |
| Purity | >95% by SDS-PAGE under reducing conditions and HPLC. |
| Shipping | The In vivo Grade Recombinant Anti-human CD64 Monoclonal Antibody, Human IgG1 Fc Silent Kappa (Clone: 22) is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Note | The human CD64 Fc blocking antibody (H22 Fc blocking antibody) is an anti-human Fc receptor antibody for human FcR blocking reagent. Various isotypes are available for certain applications. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator. |
| Order Offline | Phone: 1-617-401-8149 Fax: 1-617-606-5019 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card. |
Description
PA007393.h1Fs: Recombinant Anti-human CD64 Monoclonal Antibody (Clone: H22), Human IgG1 Fc Silent Kappa, In vivo Grade
Recombinant human IgG1 monoclonal antibody with Fc silent mutation.
Background
The recombinant 22 antibody binds to human and non-human primate CD64 or FcγRI, a cluster of differentiation molecule found on monocytes, macrophages, and neutrophils. CD64 plays a central role in macrophage antibody-dependent cellular cytotoxicity and clearance of immune complexes, and is a candidate biomarker for bacterial infection and sepsis.
References of Anti-human CD64 Monoclonal Antibody (Clone: M22)
1. An Antibody-Drug Conjugate That Selectively Targets Human Monocyte Progenitors for Anti-Cancer Therapy.
Izumi, et al. Front Immunol. 2021 Mar 5;12:618081. doi: 10.3389/fimmu.2021.618081. PMID: 33746979; PMCID: PMC7937628
“As hematopoietic progenitors supply a large number of blood cells, therapeutic strategies targeting them are potentially beneficial to eliminate unwanted leukemic cells. …Here, we introduce a dimeric pyrrolobenzodiazepine (dPBD)-conjugated anti-CD64 antibody that selectively induces the apoptosis of proliferating human monocyte-restricted progenitors. …Given the selective action on proliferating monocyte progenitors, it should be a promising tool to target cancers and inflammatory disorders with minimal side effects.”
2. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody: A potential strategy to enhance anti-TNF therapy.
Hristodorov, et al. mAbs. 2014;6(5):1283-1289. doi: 10.4161/mabs.29959. PMID: 25517313; PMCID: PMC4622438
“Tumor necrosis factor (TNF) is a pro-inflammatory cytokine that plays a critical role in inflammatory diseases, typically neutralized by therapeutic monoclonal antibodies. …However, therapeutic anti-TNF mAbs can be captured by the high-affinity IgG receptor FcγRI (CD64) expressed on activated macrophages, reducing their availability and efficacy. …In this study, we demonstrate that a single-chain antibody fragment specifically binds to CD64, preventing the capture of anti-TNF mAbs and potentially enhancing therapies.”
3. CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
Mladenov, et al. Oncotarget. 2016 Oct 25;7(43):70295-70305. doi: 10.18632/oncotarget.12197. PMID: 27564103; PMCID: PMC5341865
“Fc gamma receptor I (FcγRI, CD64) is a well-known target antigen for passive immunotherapy against acute myeloid leukemia and chronic myelomonocytic leukemia. …We recently reported the preclinical immunotherapeutic potential of microtubule associated protein tau (MAP) against a variety of cancer types including breast carcinoma and Hodgkin’s lymphoma. …Here we demonstrate that a CD64-directed human cytolytic fusion protein selectively kills CD64-positive leukemic blasts ex vivo, highlighting its potential for treating CD64-positive leukemias.”
4. Human CD64-targeted non-viral siRNA delivery system for blood monocyte gene modulation.
Heo, et al. J Control Release. 2017 Jan 28;246:125-134. doi: 10.1016/j.jconrel.2016.12.022. PMID: 28003138; PMCID: PMC5294565
“Monocytes and macrophages play key roles in various inflammatory diseases, making them highly attractive targets for RNA interference (RNAi) therapeutics. …To achieve targeted siRNA delivery, we developed a liposomal formulation surface-modified with a human CD64-specific single-chain antibody. …Our results indicate that this human CD64-targeted delivery system efficiently promotes specific cellular uptake of siRNA and gene silencing in human primary monocytes.”
5. Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia.
Kopertekh, et al. Front Plant Sci. 2023 Aug 9;14:1229490. doi: 10.3389/fpls.2023.1229490. PMID: 37637255; PMCID: PMC10444015
“Monocytic leukemia is a severe hematological malignancy that requires novel targeted therapies to overcome drug resistance and improve patient outcomes. …We designed and optimized a set of recombinant immunotoxins targeting the human CD64 receptor, utilizing transient expression in plant systems for rapid production. …Activity testing of these plant-derived immunotoxins demonstrated robust and specific cytotoxicity against CD64-expressing leukemic cells, validating this platform for biopharmaceutical development.”
For more technical references or data sheets regarding the Recombinant Anti-human CD64 Monoclonal Antibody (Clone: M22) formats, please contact our scientific support team at message@sydlabs.com.
Syd Labs provides the following in vivo grade recombinant anti-human CD16, CD32, and CD64 monoclonal antibodies:
Recombinant Anti-human CD16 monoclonal antibody (Clone: 3G8)
Recombinant Anti-human CD32 monoclonal antibody (Clone: IV.3)
Recombinant Anti-human CD64 monoclonal antibody (Clone: H22)
Syd Labs provides the following in vivo grade recombinant anti-mouse CD16, CD32, and CD64 monoclonal antibodies:
Recombinant Anti-mouse CD16/CD32 monoclonal antibody (Clone: 2.4G2)
Syd Labs provides the following recombinant anti-human CD16, CD32, and CD64 monoclonal antibodies for flow cytometry:
Recombinant Anti-human CD16 monoclonal antibody (Clone: 3G8) for flow cytometry
Recombinant Anti-human CD32 monoclonal antibody (Clone: IV.3) for flow cytometry
Recombinant Anti-human CD64 monoclonal antibody (Clone: H22) for flow cytometry
Anti-human CD64 (H22) from: Recombinant Anti-human CD64 Monoclonal Antibody, Human IgG1 Fc Silent Kappa (Clone: H22): PA007393.h1Fs Syd Labs
You may also like…
-
Select optionsQuick View -
Select optionsQuick View -
Select optionsQuick View
